Why ‘Fault in Our Stars' author John Green is obsessed with tuberculosis
Several years after an encounter that turned him into a self-professed tuberculosis nerd, John Green's son came home from school with a question. Did the best-selling author realise that the disease played a small role in the onset of the First World War?
'I was like respectfully, if that were true I would already know,' said Green, who is best known for young adult novels such as 'The Fault in Our Stars'. 'But I looked it up, and he was so totally right.'
It turned out that three of the assassins who plotted Archduke Franz Ferdinand's death – a crucial if chaotic moment in the build-up to war – were suffering from tuberculosis (TB). Historians have posited that they were prepared to die for their cause partly because they knew already that their days were numbered.
The tidbit is one of Green's favourites, but as his obsession with TB has grown, so too has his collection of anecdotes. Did you know that Ringo Starr first discovered percussion while recovering from TB in a sanatorium? Or that cowboy hats were created for the midwest sun after a hat-maker in the 1850s moved in search of cleaner air for his struggling lungs?
'I think we do underestimate the extent to which, not just tuberculosis but disease in general, has shaped human history,' said Green. 'Think of how different the world could be if Alexander the Great hadn't died of typhoid or malaria when he was still a young man… [or if] Louis XVI's son hadn't died of tuberculosis as the French Revolution was beginning.'
But while the intriguing history of the world's deadliest infection may have informed the title of Green's latest book, 'Everything is Tuberculosis', it was never the driving force for writing.
Instead, the story began with Henry Reider, an 'uncommonly charismatic' patient in Sierra Leone. The pair first met in 2019. Green was in the west African country on a trip related to maternal mortality when he visited a TB hospital – at the time, he had no idea that the curable disease still kills upwards of 1.2 million people every year, and infects another 10 million.
'I thought that TB was a disease of 19th century poets, not a disease of the present,' Green said, in his first interview with a British newspaper about the new book.
'Then I met this kid who looked to be about the same age as my son, who was nine at the time, and who had the same name as my son, Henry.'
But as Green toured the Lakka Government Hospital with Reider, he was in for a series of shocks. Henry Reider was not nine but 17 – he'd been stunted from severe malnutrition in childhood – and his experience with TB was 'devastating'.
Reider's father, distrustful of the health care system, had halted his son's treatment part way through a months-long course of drugs, allowing the infection to develop drug-resistance. Later, when the usual toxic cocktails of drugs failed him, bedaquiline – a safer treatment regimen that involves few tablets over a shorter period – was deemed too expensive.
'It was infuriating to me. You or I would receive the kind of personalised, tailored treatment that Henry was told was unaffordable without hesitation or question,' said Green. 'Meeting Henry and spending that afternoon with him really reshaped my understanding of illness.'
Reider's story forms the backbone of 'Everything is Tuberculosis', where Green argues that injustice is behind the continued presence of TB – a bacterial pathogen formally identified in 1882, but which has been killing people for centuries longer.
Although the airborne disease can infect anyone, today it is largely a disease of poverty. The World Health Organization (WHO) estimates 1.25 million people died from TB in 2023 – 81 per cent of fatalities were in south Asia and Africa, compared to just 1.4 per cent in Europe.
This has impacted everything from investment in vaccine and drug development, to the accessibility of expensive treatments and specialist doctors for patients. But it wasn't until Green spoke to a renowned TB doctor that the implications hit him: even with today's imperfect tools and knowledge gaps, the disease could be wiped out..
'I asked him, how many people would die of tuberculosis if everyone had the kind of health care that I have? And he said: 'none, zero'. And that shocked me, it means that every death from tuberculosis is optional.'
Drawing attention to this reality felt essential for Green. Still, he was unsure how the book would land.
'Every time I try to market the book, I feel almost apologetic – like I have to explain that it's a non fiction book about tuberculosis,' he said.
'[But] it feels like a natural progression, in the sense that I've been interested in illness for a long time… I wrote about cancer in 'The Fault in Our Stars', I wrote about OCD in 'Turtles All the Way Down'. And you know, this is also a book about a smart teenager who loves poetry.'
He hardly needed to be concerned. The response has been 'wildly unexpected': since it was published last month, 'Tuberculosis is Everything' has topped the New York Times bestseller list for non-fiction for a fortnight, while Green's US book tour sold out within days.
Green isn't entirely sure how he captured the public imagination, but he wonders if part of the explanation lies in the timing.
The book was published after Donald Trump's administration slashed the foreign aid budget and closed the USAID agency – an unprecedented move with huge ramifications for global health, including the fight against tuberculosis.
The US contributed roughly half of all international donor funding for TB last year, according to the WHO, which last month warned that efforts to curb the disease are now 'in peril' as health workers funded by USAID have been laid off, testing and surveillance services halted, drug development paused and access to treatment curtailed for millions.
'I never imagined that the cuts under the Trump administration would be this severe, and that they would lead to this scale of mass death. I was a little naive, I think,' said Green. 'It is absolutely devastating… it's a massive failure of global resource allocation, and a mark of shame on all of us.'
He added that it is disappointing to see the UK also reduce its aid budget, from 0.5 per cent of gross national income to 0.3 per cent in 2027.
In West Africa, Reider has recovered from TB, completed exams at the University of Sierra Leone, and launched a YouTube vlog. But Green fears for other patients – Reider's hospital is among those hit by the US aid cuts, and TB is not the only disease affected.
'A friend in Sierra Leone who has HIV called me and said: 'Look, there's two weeks left of medication, and after that they don't know'. I said Sarah [Green's wife] and I will make sure you and your mom have access to HIV medicine, of course. And he said: 'Thank you, but what about everyone else?
'The truth is, there is no way for individuals and philanthropy to set up and act at the scale that governments are acting. And so that question – 'what about everyone else?' – is a question that haunts me. I think it should haunt us all.'
But although Green is less optimistic about the promise of eliminating TB than when he finished writing the book, he has retained a sense of hope that the outlook can change – especially because cheaper diagnostics, better treatments and promising vaccine candidates are in the pipeline.
'If you think of the fight against tuberculosis as a very long staircase, we've walked a long way up that staircase since Hippocrates told his students not even to bother treating tuberculosis, because it would make them look like bad healers,' said Green.
'In the last eight weeks, we've fallen down the staircase and that's devastating. But when you fall down a staircase, you get up and start walking up the staircase again.'
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.
GMP TERBIUM-161 PRODUCT LAUNCHED BY TERTHERA BREDA, Netherlands, June 5, 2025 /PRNewswire/ -- TerThera B.V. has officially launched the world's first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide. Now, with the successful implementation of European Good Manufacturing Practices (GMP), TerThera's Terbium-161 meets the highest quality and safety standards required for clinical trials and patient care across Europe and beyond. This lowers regulatory barriers and accelerates the path to new therapies providing hospitals, clinicians, and researchers immediate access to this next-generation therapeutic radionuclide Terbium-161. A New Era in Cancer Treatment Terbium-161 NCA is a no-carrier-added, neutron-activated radionuclide uniquely suited for Radio Ligand Therapy (RLT). With an abundant emission of Auger electrons and high Linear Energy Transfer (LET), combined with similar chemical characteristics to well-known radiolanthanides, Tb-161 brings a high potential to decimate both primary tumors and (micro) metastases. When paired with proven targeting vectors like PSMA, SST, and FAPI analogues, Tb-161 demonstrates a bioequivalence while significantly increasing absorbed doses in all lesions, offering novel treatment options and strategies in cancer healthcare, improving the overall disease control and may even overcome radio-resistant disease. Global Vision, Local Innovation "This milestone is more than a regulatory achievement—it's a leap forward in our mission to bring Terbium-161 to patients worldwide," said Philippe van Overeem, CEO of TerThera. "GMP Terbium-161 is now a clinical reality, and this is just the beginning. We are actively constructing a large-scale production facility to meet the growing global demand and expand access to this promising radionuclide for optimized cancer treatments." With this launch, TerThera reaffirms its commitment to transforming the landscape of radiopharmaceuticals and leading the charge in precision oncology. About TerThera BV TerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT. support@ View original content: SOURCE TerThera Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Scientific American
a day ago
- Scientific American
Inside the Collapse of the America's Overdose Prevention Program
At an addiction conference in Nashville, Tenn., in late April, U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr., spoke about his own experience with drug use. 'Addiction is a source of misery. It's also a symptom of misery,' he said. Kennedy's very personal speech, however, ignored recent federal budget cuts and staffing reductions that could undo national drug programs' recent progress in reversing overdoses and treating substance use. Several experts in the crowd, including Caleb Banta-Green, a research professor at the University of Washington, who studies addiction, furiously spoke up during Kennedy's speech. Banta-Green interrupted, shouting 'Believe science!' before being removed from the venue. (The Department of Health and Human Services did not respond to a request for comment for this article.) 'I had to stand up and say something,' says Banta-Green, who has spent his career working with people who use drugs and was a senior science adviser at the Office of National Drug Control Policy during the Obama administration. 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. The Trump administration has defunded public health programs and made plans to consolidate or eliminate the systems that track their outcomes, making it difficult to monitor the deadly consequences of substance use, Banta-Green says. For instance, staff cuts to the Overdose Data to Action program and the Opioid Overdose Prevention and Surveillance program will hamper former tracking efforts at the Centers for Disease Control and Prevention and at local and state health departments' prevention programs. A recently fired policy analyst at the overdose prevention division at the CDC's National Center for Injury Prevention and Control— who wishes to remain anonymous, citing fear of retaliation—tells Scientific American that she used to provide policy support to teams at health departments in 49 states and shared public overdose data and information to Congress. She is a veteran who should have had protected employment status, but she lost her job during federal cuts in February. 'No one else is doing surveillance and data collection and prevention like the CDC was,' she says. 'There's so much that's been cut.' (When approached for an interview by Scientific American, a CDC spokesperson said, 'Honestly, the new administration has changed how things normally work' and did not make anyone available for questions.) What Gets Measured Gets Managed Provisional data suggest that deaths from drug use declined by almost 25 percent in 2024, though overdoses remain the leading cause of death for Americans aged 18 to 44. Cuts to the National Survey on Drug Use and Health will make it difficult to measure similar statistics in the future. Because substance use is highly stigmatized, Banta-Green says it's important to have diverse, localized and timely data from multiple agencies to accurately capture the need for services—and the ways they're actually used. 'You can't design public health or policy responses if you don't know the scale of the need,' he says. Overdose trends vary by region—for example, usage of the synthetic opioid fentanyl appeared earlier on the East Coast than the West—so national averages can obscure critical local patterns. These regional differences can offer important insights into which interventions might be working, Banta-Green says. For instance, important medications such as naloxone rapidly reverse opioid overdoses in emergency situations. But getting people onto long-term medications, including methadone and buprenorphine, which reduce cravings and withdrawal symptoms, can more effectively prevent mortality in both the short and long term. Declining deaths may also mask tragic underlying dynamics. Successful interventions may not be the only cause of a drop in overdoses; it could also be that the people who are most vulnerable to overdose have recently perished and that there are simply fewer remaining at risk. 'It's like a forest fire burning itself out,' Banta-Green says. This underscores the need for the large-scale data collection threatened by the proposed budget and staff cuts at the CDC and National Institutes of Health, says Regina LaBelle, an addiction policy expert at Georgetown University. 'What [the administration is] doing is shortsighted' and doesn't appear to be based 'on the effectiveness or the outcomes of the programs that [it's] cutting,' she says. For example, despite promising to expand naloxone access, the Trump administration's latest budget proposal cuts funding for a critical program that distributes the lifesaving medication to first aid responders. 'A Chance at Redemption' When LaBelle was acting director of the White House Office of National Drug Control Policy during the Biden administration, she led efforts to expand evidence-based programs that provided clean syringes and tested users' drugs for harmful substances. These strategies are often referred to as 'harm reduction,' which LaBelle describes as 'a way you can meet people where they are and give them the services they need to keep them from dying.' José Martínez, a substance use counselor based in Buffalo, N.Y., says harm-reduction practices helped save his life. When Martínez got his first job as a peer advocate for people using drugs, he was still in a chaotic part of his own addiction and had been sleeping on the street and the subway—and regularly getting into fights—for a decade. The day after he was hired to help provide counseling on hepatitis C, he got into a New York City shelter. As his bruises healed, he learned life skills he was never taught at home. 'For a lot of people, drug use is a coping tool,' he says. 'The drug is rarely the problem. Drug use is really a symptom.' Working with others who understood that many people need help minimizing risks gave Martínez a chance to make progress toward recovery in a way that he says abstinence-only treatment programs couldn't. 'I don't agree that somebody should be sober in order for them to do things different,' he says. Over the past six years working for the National Harm Reduction Coalition, Martínez started a national support network for other peer program workers and community members—people who share their experiences and are a trusted source of education and support for others using drugs. 'There's never no time limit,' he says. 'Everybody works on their own pace.' Though Martínez's program doesn't take federal funding, the Trump administration is cutting similar kinds of peer programs. Martínez says doing this peer work gives many users a sense of purpose and stability—and helps them avoid previous behaviors. The proposed 2026 federal budget will slash the CDC's opioid surveillance programs by $30 million. It also creates a new subdivision called the Administration for a Healthy America that will consolidate the agency's prevention work, along with existing programs at the Substance Abuse and Mental Health Services Agency (SAMHSA), which often coordinates grants for treatment programs. The programs formerly conducted through SAMHSA are also facing cuts of more than $1 billion. Advocates fear this will include a shift toward funding abstinence-only priorities, which, Martínez says, 'will definitely mean that we're going to have more overdoses.' (Some research suggests abstinence-based treatment actually puts people at a higher risk of fatal overdose than those who receive no treatment at all.) 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' —Caleb Banta-Green, addiction research professor These cuts could disproportionately affect communities already facing higher overdose rates: Martínez, who is Puerto Rican, notes that U.S. Black, Latino and Indigenous communities have experienced drug overdose death increases in recent years. In many states, overdose deaths in Black and brown communities remain high while white overdose death rates are declining. Looming cuts to Medicaid programs, LaBelle warns, are likely to worsen inequalities in health care access, which tends to make communities of color more vulnerable. In Kentucky, where Governor Andy Beshear recently celebrated a 30 percent decline in overdose deaths, Shreeta Waldon, executive director of the Kentucky Harm Reduction Coalition, says the reality is more nuanced. While national overdose deaths declined in white populations from 2021 to 2023, for example, they continued to rise among people of color. Black and Latino communities often face barriers when accessing health services, many of which have been shaped by predominantly white institutions. Waldon says it's essential for people from diverse backgrounds to participate in policy decisions and necessary to ensure that opioid abatement funds —legal funds used toward treatment and prevention—are distributed fairly. Without adequate federal funding, Waldon predicts treatment programs in Kentucky will become backlogged—potentially pushing more people into crisis situations that lead to emergency services or incarceration rather than to recovery. These financial and political pressures are not only making it harder to find support for people in crisis; they also reduce opportunities to discuss community needs. Waldon says she knows some social workers who now avoid terms such as 'Black woman' or 'marginalized' in grants and public talks out of fear of losing funding. But people currently needing treatment for substance-use disorder are not necessarily aware of the federal funding news—or 'what's about to hit them when they try to go get treatment and they're hit with barriers,' Waldon says. 'That's way more important to me than trying to tailor the way I talk.' Funding and staffing cuts don't just limit resources for the people most in need. They limit the ability to understand where someone is coming from, which undermines efforts to provide meaningful care, Martínez says. Harm reduction is more than the services and physical tools given to community members, he says. It's about the approach. 'When you look at a whole person, you plant the seed of health and dignity,' he says. 'If everybody deserves a chance at redemption, then we've got to rethink how we're approaching things.'
Yahoo
2 days ago
- Yahoo
Update on bringing together four council payroll systems
STAFF at Cumberland Council were all paid through the same payroll system for the first time since the unitary authority was formed last month, councillors have heard. Members of the council's business and resources overview and scrutiny committee met at Allerdale House in Workington on get an update on staff sickness absences on Tuesday (June 3). Before she started her update Jacqui Green, assistant director of human resources and organisational development, told members of the progress made in unifying the authority's payroll system. The work is required because when it was formed as a new unitary authority it inherited four different payroll systems from the former Carlisle City, Allerdale, Copeland and Cumbria County councils. Relating to sickness absences Ms Green said there was a big focus on early intervention and staff wellbeing and the aim was to identify issues early on. According to her report there are still four separate sickness absence policies which managers must apply. The report states: 'The human resources and organisational development (HROD) team have engaged with managers and are currently working with the council's recognised trade unions to develop one policy to manage absences. 'It is expected that a new policy will be finalised in June 2025. This new approach will have a focus on prevention and wellbeing. 'This will support a reduction in the council sickness absence rate. The introduction of the policy will be facilitated by a mandatory programme of dedicated upskilling for managers to support them in their line management duties. Trade union colleagues will also be invited to attend the training.' When councillor David Moore (Gosforth, Conservative) asked if there was a timeline for bringing the policies together Ms Green assured him she was hopeful that it should be completed by the end of the month. It was recommended that the next report, which details further progress, is presented to the committee in six months' time which was agreed.